Aurobindo Pharma Limited (NSE:AUROPHARMA)
1,479.00
-8.30 (-0.56%)
May 11, 2026, 3:30 PM IST
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 86.46B INR in the quarter ending December 31, 2025, with 8.36% growth. This brings the company's revenue in the last twelve months to 331.82B, up 7.31% year-over-year. In the fiscal year ending March 31, 2025, Aurobindo Pharma had annual revenue of 317.24B with 9.39% growth.
Revenue (ttm)
331.82B
Revenue Growth
+7.31%
P/S Ratio
2.60
Revenue / Employee
11.98M
Employees
27,707
Market Cap
863.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 317.24B | 27.22B | 9.39% |
| Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
| Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
| Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
| Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cipla | 279.67B |
| Zydus Lifesciences | 260.89B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Mankind Pharma | 139.14B |
| Divi's Laboratories | 103.14B |
| Ipca Laboratories | 95.06B |
| Emcure Pharmaceuticals | 92.16B |
Aurobindo Pharma News
- 5 days ago - Aurobindo Pharma's Unit-VII classified as 'Voluntary Action Indicated' by US FDA - Business Upturn
- 6 days ago - Top Stocks For Trade Today, May 5: Adani Ports, ONGC, Oil India, Tata Technologies, Petronet LNG, Aurobindo Pharma and more - Business Upturn
- 7 days ago - Aurobindo Pharma announces resignation of Dr. Sanjay Chaturvedi as CEO of subsidiary - Business Upturn
- 10 days ago - Aurobindo Pharma's CuraTeQ Biologics receives Health Canada nod for Bevqolva biosimilar - Business Upturn
- 24 days ago - Aurobindo Pharma receives USFDA approval for Dextromethorphan Polistirex suspension - Business Upturn
- 24 days ago - Aurobindo Pharma receives USFDA approval for Glycerol Phenylbutyrate Oral Liquid - Business Upturn
- 24 days ago - HAL, Trent & more: Top stocks on brokers' radar today - The Times of India
- 25 days ago - Stocks to watch on brokerages today, April 16: Aurobindo Pharma, Adani Enterprises, HAL, ICICI Lombard in focus - Business Upturn